Societe Generale reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Wednesday, March 14th.
Several other equities research analysts have also recently weighed in on AZN. HSBC increased their target price on shares of AstraZeneca from GBX 4,340 ($60.92) to GBX 4,380 ($61.48) and gave the company a reduce rating in a research note on Thursday, November 16th. Jefferies Group restated a hold rating and set a GBX 5,100 ($71.59) price target on shares of AstraZeneca in a research note on Thursday, November 16th. JPMorgan Chase set a GBX 4,800 ($67.38) price target on shares of AstraZeneca and gave the stock a neutral rating in a research note on Thursday, November 30th. Morgan Stanley restated an equal weight rating and set a GBX 5,000 ($70.19) price target on shares of AstraZeneca in a research note on Friday, December 1st. Finally, Shore Capital restated a hold rating on shares of AstraZeneca in a research note on Monday, December 4th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of GBX 5,224.70 ($73.34).
Shares of LON AZN traded down GBX 16.50 ($0.23) during mid-day trading on Wednesday, hitting GBX 4,990.50 ($70.05). The company had a trading volume of 1,454,612 shares, compared to its average volume of 2,310,000. AstraZeneca has a 12 month low of GBX 4,260 ($59.80) and a 12 month high of GBX 5,520 ($77.48).
The business also recently declared a dividend, which was paid on Monday, March 19th. Investors of record on Thursday, February 15th were issued a GBX 133.60 ($1.88) dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 2.8%. This is a positive change from AstraZeneca’s previous dividend of $68.90.
In related news, insider Philip A. J. Broadley purchased 415 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was acquired at an average price of GBX 4,846 ($68.02) per share, with a total value of £20,110.90 ($28,229.79).
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/astrazeneca-azn-earns-buy-rating-from-societe-generale.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.